Why Prophylactic 17P Should be Delivered at Home
Research suggests that prophylactic 17P can be useful in reducing the risk of spontaneous preterm delivery (SPTD), and one large study showed how compliance, and therefore results, can be improved.
In the United States, nearly 13% of babies are born prematurely each year. Research suggests that prophylactic 17P can be useful in reducing the risk of spontaneous preterm delivery (SPTD), and one large study showed how compliance, and therefore results, can be improved using the principles of real estate: location, location, location.
The study, led by Victor Hugo Gonzalez-Quintero, MD, compared women who received nurse-administered 17P (17 alpha-hydroxyprogesterone caproate) via a home care program with those who received injections in a physician’s office. Gonzalez-Quintero found that those with home-based care were more likely to adhere to recommended treatment criteria, received a greater number of 17P injections, and had lower rates of spontaneous preterm delivery (SPTD) than women who received 17P in a physician’s office setting. In this podcast, Gary Stanziano, MD, Medical Director for Alere Women’s and Children’s Health, discusses the results of the study and its impact on practice.
Why Prophylactic 17P Should be Delivered at Home
Click to full size
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Improved maternal cardiac arrest management reported from Obstetric Life Support training
November 19th 2024A study found that Obstetric Life Support education significantly improves health care providers' readiness and outcomes in maternal cardiac arrest management, advocating for broader implementation.
Read More
IUD placement within 48 hours nonsuperior vs 2 to 4 weeks after abortion
November 19th 2024A study reveals no significant difference in 6-month intrauterine device use between placements within 48 hours or 2 to 4 weeks after a second-trimester abortion, though earlier placement carries a higher expulsion risk.
Read More
